Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

UK first to approve CRISPR treatment for diseases: what you need to know

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease

The Applications of the CRISPR/Cas9 Gene-Editing System in Treating Human Diseases

The dawn of a cure for sickle cell disease through CRISPR‐based treatment: A critical test of equity in public health genomics

UK's Approval of Mitochondrial Donation Shows How Decisions on Gene Editing Can Be Made.

CRISPR/Cas systems usher in a new era of disease treatment and diagnosis

The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatment

Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A

Move over, CRISPR: RNA-editing therapies pick up steam

CRISPR genome-editing grows up: advanced therapies head for the clinic

Advances in CRISPR-Cas systems for blood cancer

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

Hope, despair and CRISPR — the race to save one woman's life

CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Gene-editing breakthrough for a rare hereditary disorder

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Quest to use CRISPR against disease gains ground